多部位去污染预防静脉-静脉体外膜氧合支持患者获得性感染
该研究为2010年1月至2021年12月在三个法国ECMO转诊中心开展的回顾性观察研究,纳入因ARDS接受VV-ECMO的成人患者(>18岁)。两个ICU在标准治疗基础上实施多部位去污染(MSD:口咽和胃管局部抗生素每日4次、氯己定全身洗浴每日1次、鼻部莫匹罗星5天疗程),第三个ICU仅用标准治疗(SC)。MSD组69例(1162个ECMO日)发生19例ECMO相关感染(12例VAP、7例BSI),SC组172例(2376个ECMO日)发生143例(104例VAP、39例BSI),各感染部位p<0.05;泊松回归显示MSD与ECMO相关感染发生率降低独立相关(IRR=0.42,95%CI 0.23-0.60,p<0.001)。MSD组多重耐药菌获得2例 vs SC组30例(IRR=0.13,95%CI 0.03-0.56,p=0.001),ICU死亡率两组相似(SC组43% vs MSD组45%,p=0.90),倾向性评分匹配后结果相似。作者认为MSD在ECMO患者中似乎安全,可能与ECMO相关感染和多重耐药菌获得发生率降低相关,但残余混杂可能持续存在,这些有希望的结果需随机对照试验确认。
要点
- 在三个法国ECMO转诊中心因ARDS接受VV-ECMO的成人患者中,MSD组ECMO相关感染19例(12例VAP、7例BSI,1162个ECMO日)vs SC组143例(104例VAP、39例BSI,2376个ECMO日),各感染部位p<0.05。
- 泊松回归模型中MSD与ECMO相关感染发生率降低独立相关(IRR=0.42,95%CI 0.23-0.60,p<0.001)。
- MSD组多重耐药菌获得2例 vs SC组30例(IRR=0.13,95%CI 0.03-0.56,p=0.001)。
- ICU死亡率SC组43% vs MSD组45%(p=0.90),两组相似;倾向性评分匹配后结果相似。
- 作者认为MSD在ECMO患者中似乎安全,可能与ECMO相关感染和多重耐药菌获得发生率降低相关,但残余混杂可能持续存在,需随机对照试验确认。
适用人群与场景
- 2010年1月至2021年12月在三个法国ECMO转诊中心因ARDS接受VV-ECMO支持的成人患者(>18岁)。
- 两个ICU实施MSD联合标准治疗(MSD组,69例),第三个ICU仅用标准治疗(SC组,172例)。
处置流程与药物剂量
- MSD方案:口咽和胃管局部抗生素每日4次,氯己定全身洗浴每日1次,鼻部莫匹罗星5天疗程,均在标准治疗基础上实施。
研究设计与关键结果
- 研究类型:回顾性观察研究,三个法国ECMO转诊中心,2010年1月至2021年12月,纳入241例因ARDS接受VV-ECMO的成人患者(>18岁)。
- MSD组69例(1162个ECMO日)发生19例ECMO相关感染(12例VAP、7例BSI);SC组172例(2376个ECMO日)发生143例(104例VAP、39例BSI),各感染部位p<0.05。
- 泊松回归模型中MSD与ECMO相关感染发生率降低独立相关(IRR=0.42,95%CI 0.23-0.60,p<0.001)。
- 多重耐药菌获得:SC组30例 vs MSD组2例(IRR=0.13,95%CI 0.03-0.56,p=0.001)。
- ICU死亡率:SC组43% vs MSD组45%(p=0.90),两组相似;倾向性评分匹配后结果相似。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:作者指出残余混杂可能持续存在,这些有希望的结果需随机对照试验确认。
对床旁实践的改变
- 作者认为MSD在ECMO患者中似乎安全,可能与ECMO相关感染和多重耐药菌获得发生率降低相关,但需随机对照试验确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute distress respiratory syndrome (ARDS) patients with veno-venous extra corporeal membrane oxygenation (ECMO) support are particularly exposed to ECMO-associated infection (ECMO-AI). Unfortunately, data regarding AI prophylaxis in this setting are lacking. Selective decontamination regimens decrease AI incidence, including ventilator-associated pneumonia (VAP) and bloodstream infection (BSI) in critically ill patients. We hypothesized that a multiple-site decontamination (MSD) regimen is associated with a reduction in the incidence of AI among VV-ECMO patients.
METHODS: We conducted a retrospective observational study in three French ECMO referral centers from January 2010 to December 2021. All adult patients (> 18 years old) who received VV-ECMO support for ARDS were eligible. In addition to standard care (SC), 2 ICUs used MSD, which consists of the administration of topical antibiotics four times daily in the oropharynx and the gastric tube, once daily chlorhexidine body-wash and a 5-day nasal mupirocin course. AIs were compared between the 2 ICUs using MSD (MSD group) and the last ICU using SC.
RESULTS: They were 241 patients available for the study. Sixty-nine were admitted in an ICU that applied MSD while the 172 others received standard care and constituted the SC group. There were 19 ECMO-AIs (12 VAP, 7 BSI) in the MSD group (1162 ECMO-days) compared to 143 AIs (104 VAP, 39 BSI) in the SC group (2376 ECMO-days), (p < 0.05 for all infection site). In a Poisson regression model, MSD was independently associated with a lower incidence of ECMO-AI (IRR = 0.42, 95% CI [0.23-0.60] p < 0.001). There were 30 multidrug resistant microorganisms (MDRO) acquisition in the SC group as compared with two in the MSD group (IRR = 0.13, 95% CI [0.03-0.56] p = 0.001). Mortality in ICU was similar in both groups (43% in the SC group vs 45% in the MSD group p = 0.90). Results were similar after propensity-score matching.
CONCLUSION: In this cohort of patients from different hospitals, MSD appeared to be safe in ECMO patients and may be associated with improved outcomes including lower ECMO-AI and MDRO acquisition incidences. Since residual confounders may persist, these promising results deserve confirmation by randomized controlled trials.
参考来源
- Massart N, Camus C, Nesseler N, et al. Multiple-site decontamination to prevent acquired infection in patients with veno-venous ECMO support. Ann Intensive Care. 2023. PMID: 37024761. doi:10.1186/s13613-023-01120-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。